{"id":1583,"date":"2025-06-05T11:18:01","date_gmt":"2025-06-05T09:18:01","guid":{"rendered":"https:\/\/mvz-tuebingen.de\/?p=1583"},"modified":"2025-08-14T12:14:00","modified_gmt":"2025-08-14T10:14:00","slug":"in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination","status":"publish","type":"post","link":"https:\/\/mvz-tuebingen.de\/en\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/","title":{"rendered":"In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination"},"content":{"rendered":"

Henning Zelba1<\/sup>, Borong Shao1<\/sup>, Armin Rabsteyn1<\/sup>, Annekathrin Reinhardt1<\/sup>, Carsten Greve1<\/sup>, Lisa Oenning1<\/sup>, Simone Kayser1<\/sup>, Christina Kyzirakos1<\/sup>, Pauline Latzer1<\/sup>, Tabea Riedlinger1<\/sup>, Oliver Bartsch1<\/sup>, Julian W\u00fcnsche2<\/sup>, Johannes Harter3<\/sup>, Magdalena Feldhahn3<\/sup>, Yannick Bantel3<\/sup>, Janina Joh\u00e4nning3<\/sup>, Jiri K\u00f6dding3<\/sup>, Dirk Hadaschik4<\/sup>, Martin Schulze1<\/sup>, Florian Battke3<\/sup>, Olga Maksimovic2<\/sup>, Veit Scheble2<\/sup>, Alexandra M Miller5<\/sup>, Michael Castro6 7<\/sup>, Deborah T Blumenthal8<\/sup>, Martin Glas9<\/sup>, David Reardon10<\/sup> and Saskia Biskup1 2 3 4<\/sup><\/p>\n<\/div>

Abstract<\/h3><\/div>

Isocitrate dehydrogenase (IDH) mutant glioma is a malignant primary brain tumor diagnosed in adults. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors. The first targeted IDH-inhibitor was approved by the US Food and Drug Administration in August 2024 for grade 2 gliomas, in light of results of a phase III trial which showed significant advantages in progression-free survival. However, biologic therapy is not curative, and subsequent treatment options offer only limited clinical benefit and often result in long-term toxicities. In addition, targeted treatment options for grade 3 and grade 4 IDH-mutant gliomas are still missing. In this study, we present n=52 patients with glioma (grade 2, 3 and 4) with confirmed IDH1 mutation (mutIDH1) in the newly diagnosed and recurrent setting who, in addition to standard-of- care, received a personalized neoantigen-targeting peptide vaccine. Each tumor was initially analyzed for somatic mutations by whole exome sequencing, and a peptide vaccine containing potential neoepitopes was designed, manufactured and vaccinated. Each vaccine consisted of peptides derived from numerous somatic mutations, including at least one peptide targeting the mutIDH1. Vaccine immunogenicity was determined by intracellular cytokine staining and simultaneous measurement of four T-cell activation markers (Interferon-\u03b3, Tumor Necrosis Factor, Interleukin-2, CD154) after 12-day in vitro expansion of pre and post vaccination peripheral blood mononuclear cells. Extracellular CD154 staining was used to sort mutIDH1-specific CD4+T cells. Immunomonitoring revealed that the vaccines were immunogenic and induced mainly CD4 but also CD8 T cell responses. Vaccine-induced immune responses were robust and polyfunctional. Immunogenicity against mutIDH1 was high (89%). We implemented an assay which allowed us to isolate functional antigen-specific CD4+T cells in an HLA-independent manner. Subsequent T cell receptor (TCR) repertoire sequencing revealed that CD4+T cells reacting on mutIDH1 stimulation were polyclonal. Strikingly, we detected two mutIDH1-specific TCR\u03b2 candidate sequences in three different patients. These three patients had the same human leukocyte antigen (HLA) DQA-DQB alleles. The obtained TCR\u03b2 sequences could be tracked in autologous ex-vivo single-cell transcriptomic data. Our results provide a rationale for pursuing vaccination and T cell transfer strategies targeting IDH1. Furthermore, our findings indicate that personalized neoantigen-targeting vaccines might be considered for the treatment of IDH1-mutant gliomas.<\/p>\n

Keywords:<\/strong> T cell; T cell Receptor – TCR; Vaccine.<\/p>\n<\/div><\/div><\/div>

Authors<\/h3><\/div>
    \n
  1. Zentrum f\u00fcr Humangenetik T\u00fcbingen, T\u00fcbingen, Germany<\/li>\n
  2. MVZ f\u00fcr Diagnostik, Pr\u00e4vention, Onkologie und Gastroenterologie T\u00fcbingen GmbH, T\u00fcbingen, Germany<\/li>\n
  3. CeGaT GmbH, Tubingen, Germany<\/li>\n
  4. cecava GmbH, T\u00fcbingen, Germany<\/li>\n
  5. NYU Langone Health Perlmutter Cancer Center, New York, New York, USA<\/li>\n
  6. Cellworks Group Inc, South San Francisco, California, USA<\/li>\n
  7. Personalized Cancer Medicine, PLLC, Santa Monica, California, USA<\/li>\n
  8. Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel<\/li>\n
  9. Division of Clinical Neurooncology, University Hospital Essen Department of Neurology, Essen, Germany<\/li>\n
  10. Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA<\/li>\n<\/ol>\n<\/div><\/div><\/div>

    References<\/h3><\/div>
    <\/a><\/span><\/div>

    Download publication<\/a><\/p>\n<\/div><\/div><\/div>

    <\/a><\/span><\/div>

    View this paper on NCBI<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":1112,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1583","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication"],"yoast_head":"\nIn-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination - MVZ T\u00fcbingen<\/title>\n<meta name=\"description\" content=\"Find out more about this publication on the topic of in-depth characterization of vaccine-induced neoantigen-specific T cells.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mvz-tuebingen.de\/en\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination - MVZ T\u00fcbingen\" \/>\n<meta property=\"og:description\" content=\"Find out more about this publication on the topic of in-depth characterization of vaccine-induced neoantigen-specific T cells.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/\" \/>\n<meta property=\"og:site_name\" content=\"MVZ T\u00fcbingen\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-05T09:18:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-14T10:14:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mvz-tuebingen.com\/web\/wp-content\/uploads\/2024\/09\/KV_Downloads.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"lschmidlin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"lschmidlin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/\"},\"author\":{\"name\":\"lschmidlin\",\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/#\\\/schema\\\/person\\\/3cbdb49d51f8b3b461bc1accc3e4e19d\"},\"headline\":\"In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination\",\"datePublished\":\"2025-06-05T09:18:01+00:00\",\"dateModified\":\"2025-08-14T10:14:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/\"},\"wordCount\":5511,\"publisher\":{\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mvz-tuebingen.de\\\/web\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/KV_Downloads.jpg\",\"articleSection\":[\"Publication\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/\",\"url\":\"https:\\\/\\\/mvz-tuebingen.de\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/\",\"name\":\"In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination - MVZ T\u00fcbingen\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mvz-tuebingen.de\\\/web\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/KV_Downloads.jpg\",\"datePublished\":\"2025-06-05T09:18:01+00:00\",\"dateModified\":\"2025-08-14T10:14:00+00:00\",\"description\":\"Find out more about this publication on the topic of in-depth characterization of vaccine-induced neoantigen-specific T cells.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mvz-tuebingen.de\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mvz-tuebingen.de\\\/web\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/KV_Downloads.jpg\",\"contentUrl\":\"https:\\\/\\\/mvz-tuebingen.de\\\/web\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/KV_Downloads.jpg\",\"width\":1200,\"height\":500,\"caption\":\"Keyvisual Downloads\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/\",\"name\":\"MVZ T\u00fcbingen\",\"description\":\"Diagnostik, Onkologie, Pr\u00e4vention und Gastroenterologie\",\"publisher\":{\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/#organization\"},\"alternateName\":\"MVZ Zentrum f\u00fcr Onkologie, Pr\u00e4vention, Diagnostik und Gastroenterologie T\u00fcbingen GmbH\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/#organization\",\"name\":\"MVZ Zentrum f\u00fcr Onkologie, Pr\u00e4vention, Diagnostik und Gastroenterologie T\u00fcbingen GmbH\",\"url\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"MVZ Zentrum f\u00fcr Onkologie, Pr\u00e4vention, Diagnostik und Gastroenterologie T\u00fcbingen GmbH\"},\"image\":{\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mvz-tuebingen.de\\\/en\\\/#\\\/schema\\\/person\\\/3cbdb49d51f8b3b461bc1accc3e4e19d\",\"name\":\"lschmidlin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination - MVZ T\u00fcbingen","description":"Find out more about this publication on the topic of in-depth characterization of vaccine-induced neoantigen-specific T cells.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mvz-tuebingen.de\/en\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/","og_locale":"en_US","og_type":"article","og_title":"In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination - MVZ T\u00fcbingen","og_description":"Find out more about this publication on the topic of in-depth characterization of vaccine-induced neoantigen-specific T cells.","og_url":"https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/","og_site_name":"MVZ T\u00fcbingen","article_published_time":"2025-06-05T09:18:01+00:00","article_modified_time":"2025-08-14T10:14:00+00:00","og_image":[{"width":1200,"height":500,"url":"https:\/\/mvz-tuebingen.com\/web\/wp-content\/uploads\/2024\/09\/KV_Downloads.jpg","type":"image\/jpeg"}],"author":"lschmidlin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"lschmidlin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/#article","isPartOf":{"@id":"https:\/\/mvz-tuebingen.de\/en\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/"},"author":{"name":"lschmidlin","@id":"https:\/\/mvz-tuebingen.de\/en\/#\/schema\/person\/3cbdb49d51f8b3b461bc1accc3e4e19d"},"headline":"In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination","datePublished":"2025-06-05T09:18:01+00:00","dateModified":"2025-08-14T10:14:00+00:00","mainEntityOfPage":{"@id":"https:\/\/mvz-tuebingen.de\/en\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/"},"wordCount":5511,"publisher":{"@id":"https:\/\/mvz-tuebingen.de\/en\/#organization"},"image":{"@id":"https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/#primaryimage"},"thumbnailUrl":"https:\/\/mvz-tuebingen.de\/web\/wp-content\/uploads\/2024\/09\/KV_Downloads.jpg","articleSection":["Publication"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mvz-tuebingen.de\/en\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/","url":"https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/","name":"In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination - MVZ T\u00fcbingen","isPartOf":{"@id":"https:\/\/mvz-tuebingen.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/#primaryimage"},"image":{"@id":"https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/#primaryimage"},"thumbnailUrl":"https:\/\/mvz-tuebingen.de\/web\/wp-content\/uploads\/2024\/09\/KV_Downloads.jpg","datePublished":"2025-06-05T09:18:01+00:00","dateModified":"2025-08-14T10:14:00+00:00","description":"Find out more about this publication on the topic of in-depth characterization of vaccine-induced neoantigen-specific T cells.","breadcrumb":{"@id":"https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/#primaryimage","url":"https:\/\/mvz-tuebingen.de\/web\/wp-content\/uploads\/2024\/09\/KV_Downloads.jpg","contentUrl":"https:\/\/mvz-tuebingen.de\/web\/wp-content\/uploads\/2024\/09\/KV_Downloads.jpg","width":1200,"height":500,"caption":"Keyvisual Downloads"},{"@type":"BreadcrumbList","@id":"https:\/\/mvz-tuebingen.de\/in-depth-characterization-of-vaccine-induced-neoantigen-specific-t-cells-in-patients-with-idh1-mutant-glioma-undergoing-personalized-peptide-vaccination\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/mvz-tuebingen.de\/en\/"},{"@type":"ListItem","position":2,"name":"In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination"}]},{"@type":"WebSite","@id":"https:\/\/mvz-tuebingen.de\/en\/#website","url":"https:\/\/mvz-tuebingen.de\/en\/","name":"MVZ T\u00fcbingen","description":"Diagnostik, Onkologie, Pr\u00e4vention und Gastroenterologie","publisher":{"@id":"https:\/\/mvz-tuebingen.de\/en\/#organization"},"alternateName":"MVZ Zentrum f\u00fcr Onkologie, Pr\u00e4vention, Diagnostik und Gastroenterologie T\u00fcbingen GmbH","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mvz-tuebingen.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mvz-tuebingen.de\/en\/#organization","name":"MVZ Zentrum f\u00fcr Onkologie, Pr\u00e4vention, Diagnostik und Gastroenterologie T\u00fcbingen GmbH","url":"https:\/\/mvz-tuebingen.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mvz-tuebingen.de\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"MVZ Zentrum f\u00fcr Onkologie, Pr\u00e4vention, Diagnostik und Gastroenterologie T\u00fcbingen GmbH"},"image":{"@id":"https:\/\/mvz-tuebingen.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/mvz-tuebingen.de\/en\/#\/schema\/person\/3cbdb49d51f8b3b461bc1accc3e4e19d","name":"lschmidlin"}]}},"_links":{"self":[{"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/posts\/1583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/comments?post=1583"}],"version-history":[{"count":50,"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/posts\/1583\/revisions"}],"predecessor-version":[{"id":1673,"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/posts\/1583\/revisions\/1673"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/media\/1112"}],"wp:attachment":[{"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/media?parent=1583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/categories?post=1583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mvz-tuebingen.de\/en\/wp-json\/wp\/v2\/tags?post=1583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}